Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Raza Bokhari
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- -0.61
- Country
- CA
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -10.59
Financials
Net Income
$-8.39MEBITDA
$-8.29MFree Cash Flow
$-4.96MEPS (diluted)
$-0.15Shares Outstanding (diluted)
55.06M+584.0%Operating Expenses
$11.48MCash & Debt
$10.70MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-25.37M | $-1.96 |
| 2024 | $0.00 | $-11.16M | $-0.69 |
| 2023 | $0.00 | $-5.31M | $-0.49 |
| 2022 | $0.00 | $-1.69M | $-0.16 |
| 2021 | $0.00 | $-2.06M | $-0.26 |
Valuation
MDCXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
132+163.33%Social Signal Score
Mentions (9)
- Newsproactiveinvestors.com·7d ago·Negative
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk. The company said the stage-gated design starts with about 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient open-label dose-optimiza…
View source ↗ - Newsglobenewswire.com·7d ago·Negative
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-ef
View source ↗ - Newsproactiveinvestors.com·14d ago·Negative
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma. The decision builds on the company's portfolio strategy announced earlier this month, under which Medicus is concentrating resources on program…
View source ↗ - Newsglobenewswire.com·15d ago·Neutral
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
View source ↗ - Newsproactiveinvestors.com·25d ago·Positive
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a…
View source ↗ - Newsproactiveinvestors.com·27d ago·Negative
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor popul…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications
View source ↗ - Newsproactiveinvestors.com·54d ago·Neutral
Medicus Pharma advances pipeline during Q2 with key milestones Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinical progress across its SkinJect and Teverelix programs, while raising about $40 million through equity and debt financing during the first half of 2026. The company said it received FDA “Study May Proceed” authorization for its registrational SkinJect study in patients with Gorlin Syndrome.
View source ↗ - Newsaccessnewswire.com·54d ago·Neutral
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion PHILADELPHIA, PA / ACCESS Newswire / August 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development prog
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.17 per share
Typical surprise -64.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.21 vs $-0.13miss
- Thu, May 14$-0.31 vs $-0.18miss
- Wed, Mar 25$-0.51 vs $-0.32miss
- Fri, Nov 14$-1.12 vs $-0.38miss
- Mon, Aug 11$-0.43 vs $-0.39miss
- Mon, May 12$-0.42 vs $-0.23miss
Estimates and results for MDCX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MDCX officers and directors.
- Bought
- —
- Sold
- $579k
0 trades
1 trade
- Velocity Fund Partners, Lpsold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MDCX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.